OncoMatch

OncoMatch/Clinical Trials/NCT07169500

Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients

Is NCT07169500 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies CAR-T for multiple myeloma.

Phase 1/2RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNCT07169500Data as of Jun 2026Location: China

Treatment: CAR-TEvaluate and compare the safety and efficacy of BCMA-CART ± ASCT in the treatment of newly diagnosed multiple myeloma (NDMM) in young patients

Check if I qualify

Extracted eligibility criteria

Treatments studied

Other

CAR-T

Cancer type

Multiple Myeloma

Performance status

ECOG 0–1(Restricted strenuous activity)

Demographics

Ages ≤ 50

Prior therapy

Cannot have received: car-t cell therapy

Cannot have received: bcma-targeted therapy

Lab requirements

Blood counts

Hemoglobin (Hb) ≥ 60 g/L; ANC ≥ 1.0 × 10^9/L (no G-CSF or other growth factors within 7 days prior to screening); ALC ≥ 0.5 × 10^9/L; Platelets ≥ 50 × 10^9/L (no platelet transfusion within 7 days prior to screening)

Kidney function

Creatinine clearance (CrCl) ≥ 40 ml/min

Liver function

Serum total bilirubin (TBIL) ≤ 1.5x ULN; ALT and AST ≤ 2.5x ULN

Cardiac function

LVEF ≥ 45%

Subjects must have adequate organ function and meet all of the following test results: Serum total bilirubin (TBIL) ≤ 1.5x ULN; ALT and AST ≤ 2.5x ULN; Creatinine clearance (CrCl) ≥ 40 ml/min; Prothrombin time (PT) ≤ 1.5x ULN, APTT < 1.5x ULN, INR < 1.5x ULN; Hemoglobin (Hb) ≥ 60 g/L; ANC ≥ 1.0 × 10^9/L (no G-CSF or other growth factors within 7 days prior to screening); ALC ≥ 0.5 × 10^9/L; Platelets ≥ 50 × 10^9/L (no platelet transfusion within 7 days prior to screening); LVEF ≥ 45%; SpO2 ≥ 92%

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07169500 currently recruiting?

Yes, this trial is currently recruiting patients.

Are there prior therapy exclusions?

Yes. Prior car-t cell therapy, bcma-targeted therapy disqualifies patients from enrollment.

Is there an age limit?

Yes. Patients must be 50 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify